ArticleBlood2024
Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
Article in Blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Chronic Myelomonocytic Leukemia: History, Pathobiology, Diagnostic Controversies, and Evolving Classification.Current hematologic malignancy reports · 2026Review
- CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?Blood neoplasia · 2026Article
- Should flow cytometry be required for CMML diagnosis? Position of the ELN iMDS Flow Working Group.HemaSphere · 2026Article
- ICSH Recommendations for Monocyte Cell Lineage Morphologic Identification, Nomenclature Harmonization, and Utilization as a Biomarker.International journal of laboratory hematology · 2026Review
- Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.Leukemia · 2025Article
- Application of the International Working Group MDS molecular taxonomy classes to a single institution cohort.Blood neoplasia · 2025Article
- Myeloid Neoplasms With Oligomonocytosis Exhibit Heterogenous Pathologic and Genetic Features.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
- Validation of clinicopathologic features of a genetic myelodysplastic syndrome classification in an independent cohort.Journal of hematopathology · 2025Article
- Allogeneic Transplant for CMML.Current hematologic malignancy reports · 2025Review
- Contemporary CMML Risk Stratification and Management.Current hematologic malignancy reports · 2025Review
- KDM6A Deficiency Induces Myeloid Bias and Promotes CMML-Like Disease Through JAK/STAT3 Activation by Repressing SOCS3.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management.Leukemia · 2025Review
- Can molecular patterns help to classify overlapping entities in myeloid neoplasms?Histopathology · 2025Review
- A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC.Journal of hematology & oncology · 2024Review
- Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.American journal of hematology · 2024Review
Corrections and comments
- Commented on by
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractThe World Health Organization (WHO) classification of hematolymphoid tumors and the International Consensus Classification (ICC) of 2022 introduced major changes to the definition of chronic myelomonocytic leukemia (CMML). To assess its qualitative and quantitative implications for patient care, we started with 3311 established CMML cases (according to WHO 2017 criteria) and included 2130 oligomonocytosis cases fulfilling the new CMML diagnostic criteria. Applying both 2022 classification systems, 356 and 241 of oligomonocytosis cases were newly classified as myelodysplastic (MD)-CMML (WHO and ICC 2022, respectively), most of which were diagnosed as myelodysplastic syndrome (MDS) according to the WHO 2017 classification. Importantly, 1.5 times more oligomonocytosis cases were classified as CMML according to WHO 2022 than based on ICC, because of different diagnostic criteria. Genetic analyses of the newly classified CMML cases showed a distinct mutational profile with strong enrichment of MDS-typical alterations, resulting in a transcriptional subgroup separated from established MD and myeloproliferative CMML. Despite a different cytogenetic, molecular, immunophenotypic, and transcriptional landscape, no differences in overall survival were found between newly classified and established MD-CMML cases. To the best of our knowledge, this study represents the most comprehensive analysis of routine CMML cases to date, both in terms of clinical characterization and transcriptomic analysis, placing newly classified CMML cases on a disease continuum between MDS and previously established CMML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.